scholarly journals Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

2021 ◽  
Author(s):  
Rifaat Safadi ◽  
Marius Braun ◽  
Adi Francis ◽  
Yael Milgrom ◽  
Muhammad Massarwa ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Randomised Clinical Trial ◽  
Double Blind Study ◽  
Phase 2 ◽  
Double Blind ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

2016 ◽  
Vol 51 (4) ◽  
pp. 456-464 ◽  
Author(s):  
Sara Heebøll ◽  
Martin Kreuzfeldt ◽  
Stephen Hamilton-Dutoit ◽  
Marianne Kjær Poulsen ◽  
Hans Stødkilde-Jørgensen ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Randomised Clinical Trial ◽  
High Dose ◽  
Alcoholic Fatty Liver ◽  
Resveratrol Treatment ◽  
Alcoholic Fatty Liver Disease

scholarly journals Green Tea in Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Clinical Trial

2017 ◽  
Vol 17 (12) ◽  
Author(s):  
Seyed Mohammad Tabatabaee ◽  
Seyed Moayed Alavian ◽  
Leila Ghalichi ◽  
Seyed Mohammad Miryounesi ◽  
Kazem Mousavizadeh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Disease ◽  
Fatty Liver ◽  
Randomized Clinical Trial ◽  
Green Tea ◽  
Fatty Liver Disease ◽  
Double Blind ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: A study protocol for a randomised, double-blind, placebo-controlled pilot trial

2020 ◽  
Author(s):  
Kyungsun Han ◽  
Ojin Kwon ◽  
Hyo-ju Park ◽  
So-Young Jung ◽  
Changsop Yang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Disease ◽  
Fatty Liver ◽  
Study Protocol ◽  
Fatty Liver Disease ◽  
Pilot Trial ◽  
Obese Patients ◽  
Double Blind ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Background: The high prevalence of obesity and non-alcoholic fatty acid disease has become an important public health problem. Daesiho-tang (DST) is an herbal medicine widely used to treat obesity, metabolic syndrome and liver diseases. This pilot study will assess the feasibility of using DST in obese patients with a non-alcoholic fatty liver disease (NAFLD) prior to undertaking a full-scale clinical trial. Methods: This is a study protocol for a randomised, double-blind, parallel-group, stratified, placebo-controlled pilot trial. We will recruit a total of 60 participants with body mass index ≥ 25 kg/m2 and will have NAFLD. They will take either DST or placebo (3 g, three times daily) for 12 weeks with a 4-week follow-up period. The effects of DST will be evaluated by the mean change in body weight as the primary measurement and other secondary parameters (body composition, anthropometric measurements, blood tests, hepatic fat quantification through transient elastography and a physical symptoms questionnaire). Faecal samples will be collected before and after the intervention for a gut microbial analysis. Discussion: This study will explore the effect of DST on weight loss and obesity-related markers, along with NAFLD-related clinical parameters in obese patients with NAFLD to conduct further large-scale trials. Furthermore, it will provide insight into the DST pharmacological mechanism of action through a gut microbiome analysis Trial registration: Korean Clinical Trial Registry, KCT0003554. Registered on 25 February 2019, https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=13379

Sign in / Sign up

Export Citation Format

Share Document